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Background
Gp41 of the HIV envelope, especially the MPER, con-
tains highly conserved epitopes recognized by neutraliz-
ing monoclonal antibodies such as D5, 2F5 and 4E10.
The correct presentation of the antigens is considered
to be key for eliciting neutralizing immune response.
The lipid bilayer of liposomes can mimic the virus sur-
face and therefore provides the appropriate presentation
of this membrane protein. In addition, liposomes can
integrate the adjuvant monophosphoryl lipid A (MPLA).
Methods
The gp41 derivate FPA2 was mutated to increase its
solubility and modify its structure for exposure of neu-
tralizing epitopes. The protein was expressed in E. coli.
The purified protein was solubilized with detergent.
Liposomes were prepared containing antigen FPA2 and
MPLA, a Toll-like receptor 4 agonist, using a continu-
ous ethanol crossflow injection technology. Immuno-
genicity and safety was determined in rabbits and
macaques. The liposomes formulated in HEC gel were
applied i.n. followed by two intramuscular boosts in
healthy female volunteers in a phase I study of safety
and immunogenicity.
Results
Liposomes containing FPA2 and MPLA manufactured
under GMP conditions were uniform and stable at 2-8°C.
Immunogenicity was demonstrated in rabbits and
monkey after mucosal (i.vag., i.n.) prime, followed by
intramuscular boosts. Immune response was induced
systemically and in mucosal surfaces. Preliminary data
from the clinical phase 1 study in healthy volunteers
demonstrated good safety with three nasal applications of
200 µg of the formulated protein in HEC gel and of two
i.m. boosts.
Conclusion
The liposomal formulation of the gp41 subunit of HIV
envelope together with MPLA as adjuvant proved to be
well tolerated in animals and human. Liposome-formulated
FPA2 was able to induce binding antibodies measured by
ELISA and neutralizing activity in both blood and vaginal
secretions in animals. Immunogenicity testing in humans is
ongoing.
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